StocksFundsScreenerSectorsWatchlists
MIRM

MIRM - Mirum Pharmaceuticals Inc Stock Price, Fair Value and News

25.11USD-0.72 (-2.79%)Delayed as of 12 Apr 2024, 01:58 pm ET

Market Summary

MIRM
USD25.11-0.72
Delayedas of 12 Apr 2024, 01:58 pm
-2.79%

MIRM Alerts

  • 2 major insider buys and 2 major insider sales recently.

MIRM Stock Price

View Fullscreen

MIRM RSI Chart

MIRM Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-7.43

Price/Sales (Trailing)

6.51

EV/EBITDA

-6.12

Price/Free Cashflow

-17.09

MIRM Price/Sales (Trailing)

MIRM Profitability

EBT Margin

-87.15%

Return on Equity

-65.72%

Return on Assets

-25.27%

Free Cashflow Yield

-5.85%

MIRM Fundamentals

MIRM Revenue

Revenue (TTM)

186.4M

Rev. Growth (Yr)

149.24%

Rev. Growth (Qtr)

45.74%

MIRM Earnings

Earnings (TTM)

-163.4M

Earnings Growth (Yr)

2.12%

Earnings Growth (Qtr)

-51.17%

Breaking Down MIRM Revenue

52 Week Range

24.2333.39
(Low)(High)

Last 7 days

2.2%

Last 30 days

-5.8%

Last 90 days

-5.2%

Trailing 12 Months

10.1%

How does MIRM drawdown profile look like?

MIRM Financial Health

Current Ratio

4.45

MIRM Investor Care

Shares Dilution (1Y)

23.85%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202395.8M115.8M144.7M186.4M
202233.6M48.1M62.6M77.1M
202100019.1M

Tracking the Latest Insider Buys and Sells of Mirum Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 27, 2024
bjerkholt eric
bought
49,600
24.8
2,000
chief financial officer
Mar 25, 2024
radovich peter
sold
-111,017
25.8
-4,303
president and coo
Mar 18, 2024
bjerkholt eric
bought
51,600
25.8
2,000
chief financial officer
Feb 02, 2024
howe jolanda
sold
-19,251
26.1918
-735
svp, global controller
Feb 02, 2024
radovich peter
sold
-46,883
26.1917
-1,790
president and coo
Feb 02, 2024
vig pamela
sold
-31,796
26.1918
-1,214
chief scientific officer
Feb 02, 2024
peetz christopher
sold
-157,491
26.1918
-6,013
chief executive officer
Feb 02, 2024
longpre lara
sold
-22,184
26.1918
-847
chief development officer
Jan 31, 2024
howe jolanda
acquired
-
-
1,772
svp, global controller
Jan 08, 2024
howe jolanda
sold
-14,802
28.0351
-528
svp, global controller

1–10 of 50

Which funds bought or sold MIRM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 05, 2024
GAMMA Investing LLC
new
-
427
427
-%
Apr 05, 2024
CWM, LLC
new
-
-
-
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
added
10.77
-63,962
1,050,920
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
173
737
1,211
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
added
111
3,096,730
6,256,730
0.02%
Mar 11, 2024
VANGUARD GROUP INC
added
46.23
19,589,100
73,098,700
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
279
19,332,500
26,941,000
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-27,166
363,126
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
reduced
-20.4
-5,445,040
15,791,500
0.35%
Feb 26, 2024
Virtu Financial LLC
reduced
-18.49
-64,000
203,000
0.02%

1–10 of 43

Are Funds Buying or Selling MIRM?

Are funds buying MIRM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MIRM
No. of Funds

Unveiling Mirum Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
eventide asset management, llc
5.78%
2,693,581
SC 13G/A
Feb 13, 2024
vanguard group inc
5.31%
2,476,244
SC 13G
Jan 31, 2024
blackrock inc.
5.4%
2,532,642
SC 13G
Dec 29, 2023
new enterprise associates 16, l.p.
-
0
SC 13D/A
Sep 18, 2023
biotechnology value fund l p
5.0%
2,329,616
SC 13G
Sep 05, 2023
frazier life sciences ix, l.p.
7.7%
3,566,912
SC 13D/A
Jun 23, 2023
new enterprise associates 16, l.p.
5.8%
2,186,243
SC 13D/A
May 03, 2023
flynn james e
0.00%
0
SC 13G/A
Apr 14, 2023
frazier life sciences ix, l.p.
9.4%
3,566,912
SC 13D/A
Mar 08, 2023
blackrock inc.
4.6%
1,677,907
SC 13G/A

Recent SEC filings of Mirum Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 15, 2024
10-K
Annual Report
Mar 15, 2024
S-8
Employee Benefits Plan
Feb 28, 2024
8-K
Current Report

Peers (Alternatives to Mirum Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.9B
6.8B
-3.12% -31.23%
-8.67
5.97
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
3.75% -25.01%
-43.53
10.48
76.23% 61.08%
17.3B
2.4B
7.34% -6.67%
102.9
7.13
15.42% 18.43%
12.3B
3.7B
-7.42% -25.71%
20.64
3.34
8.87% 75.42%
MID-CAP
6.7B
396.6M
-4.72% -30.06%
-12.71
16.94
425.83% 18.94%
5.0B
-
-1.05% 87.09%
-7.63
60.35
54.84% -34.79%
3.4B
270.6M
3.56% 12.92%
-14.2
12.56
440.80% -27.84%
3.2B
240.7M
-9.88% -9.91%
-10.72
13.22
-1.03% -92.09%
2.9B
726.4M
-12.76% -4.96%
-46.81
3.95
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-2.35% -9.86%
26.11
4.68
85.90% -14.05%
604.6M
983.7M
-14.62% -52.21%
-1.11
0.61
-50.36% 17.16%
419.2M
881.7K
-10.39% 387.20%
-9.4
466.16
-77.61% -5.33%
274.8M
4.9M
2.17% 32.43%
-2.03
56.47
-54.97% 51.72%
7.0M
2.1M
72.41% 90.48%
-0.26
2.14
-13.45% 66.37%

Mirum Pharmaceuticals Inc News

Latest updates
Defense World33 hours ago

Mirum Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q2
Revenue45.7%69,554,00047,725,00037,497,00031,598,00027,906,00018,780,00017,484,00012,892,0008,946,0005,000,00011,000,000
Operating Expenses40.2%102,139,00072,873,00061,770,00058,746,00062,067,00051,662,00048,925,00045,628,00048,713,00047,824,00048,401,000
  S&GA Expenses26.4%46,184,00036,528,00032,949,00030,219,00026,468,00022,513,00020,969,00019,116,00019,035,00017,353,00013,353,000
EBITDA Margin24.9%-0.81-1.08-1.47-1.37-1.80-0.73-1.21-2.06-4.36--
Income Taxes-9.6%225,000249,000316,000201,000140,00013,000-6,570,00011,00012,0009,00011,000
Earnings Before Taxes-51.8%-35,434,000-23,339,000-73,722,000-29,929,000-36,291,000-35,693,000-33,492,000-36,595,00057,558,000-47,099,000-43,883,000
EBT Margin22.8%-0.87-1.13-1.52-1.41-1.84-0.77-1.24-2.08-4.39--
Net Income-51.2%-35,659,000-23,588,000-74,038,000-30,130,000-36,431,000-35,706,000-26,922,000-36,606,00057,546,000-47,108,000-43,894,000
Net Income Margin22.7%-0.88-1.13-1.52-1.35-1.76-0.67-1.10-2.08-4.39--
Free Cashflow8.8%-16,618,000-18,221,000-2,399,000-33,815,000-34,512,000-26,044,000-20,189,000-39,669,000-33,150,000-34,220,000-40,199,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-0.6%64765144433435336429727829523524822224114215617314715810452.00
  Current Assets-0.3%38838938417219021614715516719722821823613815216211912985.0052.00
    Cash Equivalents-5.5%28630329749.0028.0036.0055.0046.0031.0056.0092.0091.0014249.0083.0072.0012.0031.0042.0052.00
  Inventory0.3%22.0022.009.007.006.007.005.002.002.00-----------
  Net PPE-10.3%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.000.00-
Liabilities4.3%39838236519221119518716917417915288.0069.0022.0020.0017.0016.0012.0012.002.00
  Current Liabilities16.6%87.0075.0058.0049.0065.0051.0045.0035.0043.0050.0029.0035.0018.0019.0017.0014.0013.0011.0011.002.00
Shareholder's Equity-7.6%24926979.0014114216911110912056.0096.00134172120136156130146--
  Retained Earnings-6.8%-556-520-497-422-392-356-320-293-257-314-267-223-173-135-114-91.21-69.90-51.95-36.86-17.35
  Additional Paid-In Capital1.5%8037915765645355264324033773713633583452562502472001982.000.00
Shares Outstanding0.3%47.0047.0038.0038.0037.0035.0032.0031.0031.0030.0030.0030.00--------
Float-------609-0.00-----244-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations8.8%-16,618-18,221-2,331-33,774-34,270-26,025-20,172-39,669-33,147-34,202-40,199-25,210-36,279-17,451-16,994-18,351-13,698-15,221-8,017-2,426-
  Share Based Compensation15.9%9,7208,3858,3578,5616,8976,9086,6416,5615,5647,4154,8235,2853,5793,4282,9742,5732,0672,1441,641218-
Cashflow From Investing98.9%-2,000-182,76235,54742,01526,758-79,52923,97136,500108,023-2,237-24,455-32,784-4,946-18,91427,97333,761-5,144-64,192-58,401-44.00-
Cashflow From Financing-99.1%1,777207,129114,70712,987-32986,0665,24618,10461534565,9126,594134,5082,09625.0044,659-68,41758,760--

MIRM Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues [Abstract]   
Total revenue$ 186,374$ 77,062$ 19,138
Operating expenses:   
Cost of sales47,03912,3741,903
Research and development102,609106,842131,428
Selling, general and administrative145,88089,06659,220
Total operating expenses295,528208,282192,551
Loss from operations(109,154)(131,220)(173,413)
Other income (expense):   
Interest income13,7353,857366
Interest expense(15,105)(15,979)(17,590)
Change in fair value of derivative liability0906(732)
Loss from termination of revenue interest purchase agreement(49,076)00
Gain from sale of priority review voucher, net00108,000
Other (expense) income, net(2,824)365(582)
Net loss before provision for income taxes(162,424)(142,071)(83,951)
Provision for (benefit from) income taxes991(6,406)37
Net loss$ (163,415)$ (135,665)$ (83,988)
Net loss per share:   
Basic$ (4)$ (4.01)$ (2.77)
Diluted$ (4)$ (4.02)$ (2.77)
Weighted-average shares outstanding:   
Basic40,885,12433,839,07230,321,722
Diluted40,885,12433,982,49330,321,722
Product   
Revenues [Abstract]   
Total revenue$ 178,874$ 75,062$ 3,138
License   
Revenues [Abstract]   
Total revenue$ 7,500$ 2,000$ 16,000

MIRM Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 286,326,000$ 28,003,000
Short-term investments0123,716,000
Accounts receivable67,968,00023,994,000
Inventory22,312,0005,565,000
Prepaid expenses and other current assets10,935,0008,947,000
Total current assets387,541,000190,225,000
Restricted cash equivalents0100,000,000
Property and equipment, net706,000914,000
Operating lease right-of-use assets1,284,0001,431,000
Intangible assets, net252,925,00058,954,000
Other assets4,165,0001,382,000
Total assets646,621,000352,906,000
Current liabilities:  
Accounts payable7,416,0008,690,000
Accrued expenses78,544,00054,018,000
Operating lease liabilities1,104,000931,000
Derivative liability01,090,000
Total current liabilities87,064,00064,729,000
Revenue interest liability, net0140,351,000
Operating lease liabilities, noncurrent617,0001,257,000
Convertible notes payable, net306,421,0000
Other liabilities3,849,0004,532,000
Total liabilities397,951,000210,869,000
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2023 and 2022;00
Common stock, $0.0001 par value; 200,000,000 shares authorized; 46,723,143 and 36,956,345 shares issued and outstanding as of December 31, 2023 and 20225,0004,000
Additional paid-in capital803,260,000535,074,000
Accumulated deficit(556,239,000)(392,824,000)
Accumulated other comprehensive income (loss)1,644,000(217,000)
Total stockholders’ equity248,670,000142,037,000
Total liabilities and stockholders’ equity$ 646,621,000$ 352,906,000
MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
 CEO
 WEBSITEmirumpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES213

Mirum Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Mirum Pharmaceuticals Inc? What does MIRM stand for in stocks?

MIRM is the stock ticker symbol of Mirum Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirum Pharmaceuticals Inc (MIRM)?

As of Thu Apr 11 2024, market cap of Mirum Pharmaceuticals Inc is 1.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MIRM stock?

You can check MIRM's fair value in chart for subscribers.

What is the fair value of MIRM stock?

You can check MIRM's fair value in chart for subscribers. The fair value of Mirum Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mirum Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MIRM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mirum Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MIRM is over valued or under valued. Whether Mirum Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Mirum Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIRM.

What is Mirum Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, MIRM's PE ratio (Price to Earnings) is -7.43 and Price to Sales (PS) ratio is 6.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIRM PE ratio will change depending on the future growth rate expectations of investors.